PatrickBJohnstonMD

Hematology • Rochester, MN

Assistant Professor, Internal Medicine, Mayo Medical School

Join to view full profile

Dr. Johnston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Johnston's full profile

Already have an account?

Office
200 1st St Sw
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Hematology and Medical Oncology, 1998 - 2001
Mayo Clinic College of Medicine and Science (Rochester)Residency, Internal Medicine, 1995 - 1998
University of Alabama School of MedicineClass of 1995

Certifications & Licensure

AZ State Medical License 1997 - Present
MN State Medical License 1996 - 2025
American Board of Internal Medicine Hematology

Clinical Trials

Trial of Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD) in Patients With Relapsed Non-Hodgkins Lymphoma Start of enrollment: 2005 Mar 01
Completed
Phase 2
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Start of enrollment: 2011 Jan 17
Completed
Phase 2
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma Start of enrollment: 2012 Mar 01
Completed
Phase 1
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) Start of enrollment: 2013 May 01
Completed
Phase 1
Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2016 Feb 04
Terminated
Phase 1
Nivolumab & Brentuximab Vedotin Consolidation After Autologous SCT in Patients With High-Risk Classical Hodgkin Lymphoma Start of enrollment: 2017 Apr 03
Active, not recruiting
Phase 2
A Study of TAK-981 Given With Rituximab in Adults With Relapsed or Refractory CD20-Positive Non-Hodgkin Lymphoma Start of enrollment: 2019 Oct 15
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
Evaluate the Safety and Clinical Activity of HH2853 Start of enrollment: 2020 Sep 08
Recruiting
Phase 1, Phase 2
Roles: Contact
DALY II USA/ MB-CART2019.1 for DLBCL Start of enrollment: 2021 May 25
Recruiting
Phase 2
Roles: Contact
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) Start of enrollment: 2021 Dec 29
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy.
Aung M Tun, Yucai Wang, Seth Maliske, Ivana Micallef, David J Inwards
Transplantation and Cellular Therapy. 2024-10-01
Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy.
Omran Saifi, William G Breen, Scott C Lester, William G Rule, Bradley J Stish
Blood Advances. 2024-09-24
1 citations
Anti-CD19 chimeric antigen receptor T-cell therapy in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study.
Aung M Tun, Romil D Patel, Frederique St-Pierre, Evguenia Ouchveridze, Alex Niu
American Journal of Hematology. 2024-09-01

Journal Articles

Primary Systemic Amyloidosis in Patients with Waldenström Macroglobulinemia
Angela Dispenzieri, Eli Muchtar, Ronald Go, Saurabh Zanwar, Surbhi Sidana, Francis Buadi, Stephen M Ansell, Prashant Kapoor, David Dingli, Thomas Habermann, Shaji Kuma..., Nature
Phase 2 Study of Everolimus for Relapsed or Refractory Classical Hodgkin Lymphoma
Patrick B. Johnston, Radhakrishnan Ramchandren, Lauren C. Pinter-Brown, BioMed Central
Phase I Study of Pomalidomide and Dexamethasone for relapsed/refractory Primary CNS or Vitreo-Retinal Lymphoma
Lisa M DeAngelis, Han W Tun, David Schiff, Kurt A Jaeckle, Christian Grommes, Patrick B Johnston, Craig B Reeder, Thomas E Witzig, Blood

Abstracts/Posters

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma
Patrick Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience
Patrick Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma
Patrick Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Mayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013
Hematologic Malignancies: New Therapies and the Evolving Role of Transplant
Mayo School of Continuous Professional Development, Chicago, Illinois - 10/11/2013